Has Thomas Herzog, MD received payments from drug or device companies?

Yes. Drug and device makers reported $584,886 in general payments to Thomas Herzog, MD across 538 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Thomas Herzog, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Thomas Herzog, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Thomas Herzog, MD

Gynecologic Oncology · Cincinnati, OHNPI 1619909850

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $459,531 of the $584,886 with a category attached, or 78.6%. 46 manufacturers reported payments, led by AstraZeneca at 31.9% of the total. Among gynecologic oncology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$584,886in general payments, 2019–2025

Across 538 payments — averaging $1087.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$187K
GSK$88K
Merck$45K
Eisai Inc.$36K
Aadi Bioscience, Inc.$32K
Astrazeneca UK Limited$28K
plus $169K from 40 others

$1,082,236in research payments, 2019–2025

Across 87 payments — averaging $12,439 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

GSK$599K
Novartis$171K
Alkermes, Inc.$153K
Merck$54K
Genmab U.S., Inc.$36K
Array Biopharma Inc$31K
plus $39K from 6 others

What the payments were for

Consulting fees$459,53179%
Speaking & faculty fees$79,38114%
Travel & lodging$29,9295%
Food & beverage$15,9703%
Education$760%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	185	$186,695
GSK	47	$87,942
Merck	39	$45,021
Eisai Inc.	18	$35,663
Aadi Bioscience, Inc.	19	$32,490
Astrazeneca UK Limited	9	$28,245
Clovis Oncology, Inc.	36	$26,665
Tesaro, Inc.	31	$17,867
Alkermes, Inc.	12	$13,590
Daiichi Sankyo Inc.	17	$12,355
Seagen Inc.	13	$12,268
AbbVie	17	$8,192
Genmab U.S., Inc.	8	$6,494
Incyte Corporation	5	$6,360
Biom'up SA	10	$6,329
Pharmaand GmbH	3	$6,074
Biom'up France SAS	2	$5,511
Pfizer	2	$4,185
Beone Medicines USA, Inc.	2	$4,000
Beigene USA, Inc.	2	$3,900
Novartis	2	$3,468
Medical Device Business Services, Inc.	2	$3,216
Myriad Genetic Laboratories, Inc.	5	$3,188
Immunocore Limited	2	$2,885
Genentech, Inc.	2	$2,839
Novocure Inc.	6	$2,447
Gilead	4	$2,440
Novocure GmbH	1	$2,400
Immunogen, Inc.	3	$2,291
Biontech SE	2	$2,160
E.r. Squibb & Sons, L.L.C.	4	$2,053
Genentech USA, Inc.	7	$1,947
Karyopharm Therapeutics Inc.	3	$1,746
Aspira Women's Health Inc	1	$1,500
Johnson & Johnson(2 entities)	4	$119
Myriad Women's Health, Inc.	1	$84
Corcept Therapeutics	1	$55
Caris MPI, Inc.	1	$41
Puma Biotechnology, Inc.	2	$32
Tactile Systems Technology Inc	2	$29
Amgen	1	$25
Channel Medsystems, Inc.	1	$21
Pharmacyclics LLC, An Abbvie Company	1	$21
Sanofi	1	$15
Dova Pharmaceuticals	1	$15
Histosonics, Inc.	1	$1

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LYNPARZA$166,220
Rubraca$31,422
FYARRO$30,028
LENVIMA$29,816
JEMPERLI$24,600
ZEJULA$13,589
KEYTRUDA$11,871
Enhertu$9,810
HEMOBLAST$6,027
EPKINLY$6,000
HemoBlast Bellows$5,511
Avastin$4,448
Elahere$4,384
TUKYSA$4,050
TECENTRIQ$3,970
STRATAFIX$3,216
HARMONIC Product Family$3,216
ENSEAL Product Family$3,094
SURGICEL Family of Absorbable Hemostats$3,094
TIVDAK$3,083

How this compares

$584,886 in reported general payments places this provider in the 95th percentile of 62 gynecologic oncology providers in Ohio.

See all gynecologic oncology providers in Ohio →

Medicare billing

Part B allowed, 2024

$57,304

Medicare patients

112

Services billed

427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in Cincinnati

Amanda JacksonCincinnati$92K
Leeya PinderCincinnati$14K
Ajit GubbiCincinnati$12K
Eric EisenhauerCincinnati$9K
Kevin SchulerCincinnati$2K
Caroline BillingsleyCincinnati$812
Jack BasilCincinnati$382
James PavelkaCincinnati$33
David OmalleyHilliard$650K
Floortje BackesHilliard$181K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →